Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Multiple Myeloma
Interventions: Teclistamab, Daratumumab, Pomalidomide, Lenalidomide, Bortezomib, Nirogacestat; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Denver, Colorado + 10 more

Conditions: Pulmonary Embolism
Interventions: TS23, Placebo; Drug
Lead sponsor: Translational Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 9 more

Conditions: Atrial Fibrillation (AF), Heart Failure, Catheter Ablation, Guideline Implementation
Interventions: LAP-Triggered Heart Failure Optimization Pathway; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Searching for and Selecting Child Care in the US
Interventions: Not listed
Lead sponsor: National Opinion Research Center; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Preterm Birth, Child Development
Interventions: Docosahexaenoic Acid + Arachidonic Acid (DHA+AA), Placebo; Drug · Dietary Supplement
Lead sponsor: Sarah Keim; Other
Eligibility: 8 Years to 10 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
Interventions: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT], Placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Obesity
Interventions: Gold-Standard Online Behavioral Obesity Treatment; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Autism
Interventions: Placebo, Docosahexanoic Acid; Dietary Supplement
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 5 Years to 17 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Gastrointestinal Neoplasms
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Assisted Suicide
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Interventions: 4D-150 IVT, Aflibercept IVT; Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 5
States / cities: Hagerstown, Maryland • Eugene, Oregon • Erie, Pennsylvania + 2 more

Conditions: Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Tremelimumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 20
States / cities: Orange, California • Aurora, Colorado • Hartford, Connecticut + 16 more

Conditions: Sickle Cell Disease
Interventions: Tebapivat, Tebapivat Matched Placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Farmington, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more

Conditions: Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Radiation Therapy; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 169
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Berkeley, California + 129 more

Conditions: Down Syndrome (DS), Alzheimer's Disease (AD)
Interventions: Remote Exercise Sessions, Caregiver Education Sessions; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Spinal Cord Injury
Interventions: Daily acute intermittent hypoxia (dAIH), dSHAM, Walking; Other
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia • Cambridge, Massachusetts

Conditions: Breast Cancer
Interventions: Decision Aid (DA), Standard of Care (SOC); Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Aurora, Colorado • Denver, Colorado • Highlands Ranch, Colorado

Conditions: Osteoarthritis, Hip, Avascular Necrosis of Hip, Avascular Necrosis of the Femoral Head, Post-traumatic; Arthrosis
Interventions: Avenir Complete Femoral Stem; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 20 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2036
U.S. locations: 3
States / cities: Jackson, Mississippi • Saint Joseph, Missouri • Portland, Oregon

Conditions: Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Interventions: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS); Combination Product
Lead sponsor: Delcath Systems Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Palo Alto, California • Tampa, Florida • Durham, North Carolina + 2 more

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Nivolumab, Surgical Resection, Radiation (5 days), Radiation (3 days); Drug · Procedure · Radiation
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Asthma in Children
Interventions: BACK-S, BACK-E; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 5 Years to 12 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Ault, Colorado • Colorado Springs, Colorado • Ellicott, Colorado + 9 more

Conditions: Extensive Stage Lung Small Cell Carcinoma
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 561
States / cities: Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 362 more

Conditions: Urothelial Carcinoma
Interventions: Livmoniplimab, Budigalimab, Docetaxel, Paclitaxel, Gemcitabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Springdale, Arkansas • San Francisco, California • New Haven, Connecticut + 8 more

Search by objective public record fields.

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

Left Atrial Pressure-Guided Heart Failure Optimization During Atrial Fibrillation Ablation (LAP AF-HF)

Case Studies of Child Care and Development Fund Lead Agencies' Consumer Education Strategies

Omega Tots Long Term Follow-up

Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Program for Fully Understanding Eating and Lifestyle Change (FUEL)

Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial

Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Assisted Suicide in Switzerland

4D-150 in Patients With Diabetic Macular Edema

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Adapting RDAD for DS

AIH-induced Walking Recovery After Subacute SCI

A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer

Avenir Complete Post-Market Clinical Follow-Up Study

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Reducing Asthma Attacks in Disadvantaged School Children With Asthma

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)